|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Drug Combo May Be Best for Plaque Regression, University of Calgary Study
5/2/2011 8:19:37 AM
Doctors Lounge -- The combination of atorvastatin plus etidronate appears to be superior to atorvastatin alone for causing the regression of thoracic and abdominal aortic plaques, according to research presented at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, held from April 28 to 30 in Chicago. In a prospective, open-label, blind-end point study, Tetsuya Kawahara, M.D., of the University of Calgary in Canada, and colleagues randomized 251 patients with asymptomatic hypercholesterolemia to receive 20 mg of atorvastatin per day or 20 mg of atorvastatin plus 400 mg of etidronate per day. The primary end point was the change of atherosclerotic plaques after 24 months of treatment.
|
|
|
|
|
|
|
|
|
|
|